NCT00509899View on ClinicalTrials.gov

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

154

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

February 28, 2017

Conditions

MyelofibrosisPolycythemia VeraThrombocytosis

Interventions

DRUG

Ruxolitinib

5 and 25 mg tablets with a daily dosing range from 10 to 200 mg qd or bid.

Trial Locations (2)

Unknown

Rochester

Houston

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY